Risk Factors and Predictors of Thrombosis in Myeloprolferative Neoplasms

A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia

NCT05350956 ·Status: UNKNOWN ·Phase: PHASE2

Avatrombopag to Promote Platelet Engraftment After Allo-HSCT

NCT05143892 ·Status: UNKNOWN ·Phase: PHASE2

Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)

NCT05419648 ·Status: COMPLETED

An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA

NCT05333861 ·Status: NOT_YET_RECRUITING

A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer

NCT05394285 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia

NCT05018936 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia

NCT03288441 ·Status: UNKNOWN

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

NCT04446650 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Eltrombopag for Chemotherapy-induced Thrombocytopenia

NCT04600960 ·Status: RECRUITING ·Phase: PHASE2

A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy

NCT07101627 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Bleeding In Thrombocytopenia Explained

NCT03505086 ·Status: RECRUITING

Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)

NCT03469661 ·Status: COMPLETED

A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

NCT02039076 ·Status: COMPLETED ·Phase: PHASE1

Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy

NCT06476535 ·Status: ACTIVE_NOT_RECRUITING

Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment

NCT07059910 ·Status: NOT_YET_RECRUITING

Explore the Relationship Between Platelet Count and Bleeding Score in ITP

NCT06273956 ·Status: RECRUITING

Immune Thrombocytopenia Management in Adults

NCT05861297 ·Status: UNKNOWN ·Phase: PHASE4

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

NCT07133659 ·Status: RECRUITING ·Phase: PHASE4

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

NCT00037791 ·Status: COMPLETED ·Phase: PHASE3

Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma

NCT05969158 ·Status: UNKNOWN ·Phase: PHASE2

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

NCT00039910 ·Status: COMPLETED ·Phase: PHASE3

Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma

NCT04797182 ·Status: UNKNOWN ·Phase: PHASE2

Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke

NCT07070193 ·Status: NOT_YET_RECRUITING

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

NCT02323178 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia

NCT04896528 ·Status: UNKNOWN ·Phase: PHASE2